Humabs BioMed Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 3
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Humabs BioMed General Information

Description

Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The company's human monoclonal antibodies have passed natural selection by the human immune system in response to viral and bacterial diseases, in addition it also developes anti-infective immunotherapies for the traetment of induce protective and therapeutic immune responses which solutions are non-existent or inadequate, enabling patients and pharmaceutical companies to get drugs for the treatment of rare diseases.

Contact Information

Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Biotechnology
Parent Company
Primary Office
  • Via Mirasole 1
  • 6500 Bellinzona
  • Switzerland
+41 091 000 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Humabs BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Humabs BioMed‘s full profile, request access.

Request a free trial

Humabs BioMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The comp
Other Pharmaceuticals and Biotechnology
Bellinzona, Switzerland
3 As of 2017
000000&0

00000000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magn
0000 000000000
Schlieren, Switzerland
0 As of 0000
000.00
00000000000 000.00

0000000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit e
0000 000000000
Jena, Germany
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Humabs BioMed Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Virometix Venture Capital-Backed Schlieren, Switzerland 0 000.00 00000000000 000.00
0000000 Formerly VC-backed Jena, Germany 00 00000 000000 - 000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000000000000 Venture Capital-Backed Saint Louis, MO 0 00.000 00000 00000 00.000
You’re viewing 5 of 49 competitors. Get the full list »

Humabs BioMed Executive Team (3)

Name Title Board Seat Contact Info
Davide Corti Ph.D Senior Vice President and Chief Scientific Officer
Nadia Passini Ph.D Director of Research and Development Operations and Translational Science
Filippo Riva Managing Director, Chief Financial Officer and Chief Executive Officer
To view Humabs BioMed’s complete executive team members history, request access »

Humabs BioMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial